Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 65% less
These brands contain the same active ingredient (Fluconazole). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Oraf is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Adults: Vaginal Candidiasis: 150 mg as a single dose. Oropharyngeal Candidiasis: 200 mg on the first day followed by 100 mg daily for 14 days. Oesophageal Candidiasis: 200 mg on the first day followed by 100 mg daily for 14 to 30 days. Tinea corporis, Tinea cruris, Tinea pedis and Other Tinea: 150 mg weekly for 4 to 6 weeks. Kerion: 50 mg daily for 20 days. Pityriasis versicolor: 400 mg as a single dose. Onychomycosis: 150 mg weekly for 12 months. Invasive candidal infections and cryptococcal infections, including meningitis: given orally or by IV infusion, 400 mg on the first day then 200 to 400 mg daily. Prevention of cryptococcal meningitis: given orally or by IV infusion, 200 mg daily. Prevention of fungal infections in immunocompromised patients: given orally or by IV infusion, 50 to 400 mg daily. Children over 1 year: In Superficial Candidiasis, 1 to 2 mg per kg daily. In Systemic Candidiasis and Cryptococcal infection, 3 to 6 mg per kg daily. In serious life threatening infections, up to 12 mg per kg daily has been given to children aged 5 to 13 years, with a maximum of 400 mg daily. As a rough guide, a child of 1 year weighing about 9 kg may be given half a measuring spoonful, a child of 1 to 2 years weighing about 12 kg one measuring spoonful, a child of 2 to 3 years weighing about 14 kg one and a half measuring spoonfuls, a child of 3 to 4 years weighing about 16 kg two measuring spoonfuls, and a child of 4 to 6 years weighing about 20 kg two and a half measuring spoonfuls. Use in specific populations. Elderly patients: the normal dose should be used if there is no evidence of renal impairment. Renal impairment: no adjustment is needed for single dose therapy. In multiple dose therapy for patients with renal impairment, normal doses should be given on days 1 and 2 of treatment, and thereafter the dosing interval should be adjusted according to creatinine clearance. With creatinine clearance above 41 ml per minute, dose every 24 hours. With creatinine clearance of 21 to 40 ml per minute, dose every 48 hours. With creatinine clearance of 10 to 20 ml per minute, dose every 72 hours. Patients on regular dialysis should receive one dose after every dialysis session. In children, renal clearance may be proportionately more rapid than in adults, and doses up to 12 mg per kg are recommended.
Side Effects
Fungicap is generally well tolerated. The most common side effects associated with Fungicap involve the gastrointestinal tract, including nausea, abdominal discomfort, diarrhoea and flatulence. Other adverse events such as rash are rarely encountered, with an incidence of less than 1%. In rare cases, as with other azoles, anaphylaxis has been reported.
Cautions & Contraindications
Warnings & Precautions
In some patients, particularly those with serious underlying diseases such as AIDS and cancer, abnormalities of liver, kidney, blood and other biochemical test results have been observed during treatment with fluconazole, but the clinical significance and the relationship to treatment are uncertain. Very rarely, patients who died with severe underlying disease and who had received multiple doses of fluconazole were found on post-mortem examination to have liver damage, including hepatic necrosis. These patients were taking multiple other medications, some known to be potentially harmful to the liver, and/or had underlying diseases that could have caused the liver damage on their own. Because a causal link with fluconazole cannot be ruled out, the balance of risks and benefits of continuing fluconazole treatment should be reviewed in any patient who develops a significant rise in liver enzymes. Patients have rarely developed exfoliative skin reactions, such as Stevens Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole. Patients with AIDS are more prone to developing severe skin reactions to many drugs. If a patient being treated for a superficial fungal infection develops a rash that is considered attributable to fluconazole, treatment with this medicine should be stopped. In patients with invasive or systemic fungal infections who develop a rash, they should be monitored closely, and fluconazole should be stopped if blistering lesions or erythema multiforme develop. Use during breastfeeding: Fluconazole passes into human breast milk at concentrations similar to those in plasma, so its use in breastfeeding mothers is not recommended. Driving and use of machinery: Experience with fluconazole suggests that treatment is unlikely to affect a patient's ability to drive or operate machinery.
Contraindications
Fluconazole should not be given to anyone who is known to be hypersensitive to it, or to other triazole antifungal compounds.